Drug Trial Radar · NCT02452242
Safety, PK and PD Study of ABX464 in Untreated HIV Patients
Last checked: Nov 19, 2026Latest source record: May 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Jan 2015
Primary completion
Dec 2015
Study completion May 2016
Sponsor
- Lead sponsor
- Abivax S.A.Industry
- Sponsor type
- Industry
- First posted
- May 22, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ABX464 is a first in class that showed efficacy as an anti-HIV therapy. The present study is intended to assess the safety, the tolerability, and pharmacokinetic parameters and to evaluate the effect on viral load of repeated oral administrations of ABX464 in patients infected by HIV, not previously treated for their HIV. Two types of design are intended in this protocol: dosing every 3 days or dosing every day. The goal is to determine the best dosing regimen to reduce viral load and minimize adverse events.
Conditions
- Human Immunodeficiency Virus Infections
Interventions
ABX464Drug
25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
PlaceboOther
1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability profile of ABX464 as assessed by the change from baseline in laboratory values, in vital signs and ECG parameters at week 3 and by the number of patients with adverse events.Time frame: Week 3
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
CAP Research Ltd
Curepipe, Mauritius
HIV-NAT, Thai Red Cross AIDS Research Center
Bangkok, Thailand
Siriraj Hospital, Mahidol University
Bangkok, Thailand
Chiang Mai University
Chiang Mai, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.